Milan Scheidegger has a multidisciplinary background in medicine (MD), neuroscience (PhD), philosophy (MA), psychiatry and psychotherapy (FMH). As a Senior Physician he is currently leading the Psychedelic Research & Therapy Development group at the Department of Adult Psychiatry and Psychotherapy (Psychiatric University Clinic Zurich and the University of Zurich). Besides innovations in the field of psychedelic drug development, he co-founded Reconnect Labs AG and the non-profit organization Reconnect Foundation. His contributions to the field of consciousness research were acknowledged by a Young Investigators Award from the Swiss Society of Biological Psychiatry (2013), the Inger Salling Prize for Psychiatry (2019), and the European Varela Award (2021). He is engaged in public discourse and education around psychedelic therapy and has given talks to both academic and non-academic audiences.
Milan Scheidegger has a multidisciplinary background in medicine (MD), neuroscience (PhD), philosophy (MA), psychiatry and psychotherapy (FMH). As a Senior Physician he is currently leading the Psychedelic Research & Therapy Development group at the Department of Adult Psychiatry and Psychotherapy (Psychiatric University Clinic Zurich and the University of Zurich). Besides innovations in the field of psychedelic drug development, he co-founded Reconnect Labs AG and the non-profit organization Reconnect Foundation. His contributions to the field of consciousness research were acknowledged by a Young Investigators Award from the Swiss Society of Biological Psychiatry (2013), the Inger Salling Prize for Psychiatry (2019), and the European Varela Award (2021). He is engaged in public discourse and education around psychedelic therapy and has given talks to both academic and non-academic audiences.